Huadong Medicine announced that its wholly-owned subsidiary Hangzhou Sino-US Huadong Pharmaceutical Jiangdong Co., Ltd. received the "Acceptance Notice" from the State Food and Drug Administration, and its application for marketing authorization of semaglutide injection has been accepted. The drug is a long-acting glucagon-like peptide-1 receptor agonist, mainly used to control blood sugar in patients with type 2 diabetes and weight management in obese or overweight patients. The original developer of semaglutide injection is Novo Nordisk, and it has been launched in many markets around the world. The total direct investment in the research and development of this drug is approximately 196 million yuan. The acceptance of this listing application marks an important progress in the research and development of the drug, which will help enhance the company's competitiveness in the field of endocrine therapy in the long run.